New schizophrenia biomarker test sparks controversy

Rules-Based Medicine has reached a major milestone with the commercial release of VeriPsych, a diagnostic test that looks at a complex array of 51 biomarkers to help physicians come up with a diagnosis of early-stage schizophrenia. But the test, the first blood-based tool of its type, has triggered a sharp debate among the experts about its accuracy and usefulness.

Based on 10 years of research originally undertaken at Cambridge University and later out-licensed to a subsidiary of the Austin-based diagnostics group, the test is sold for $2,500 and a recent study pegged its accuracy rate at 83 percent. It's intended to give psychiatrists and objective method for identifying patients and beginning treatment--to be used in conjunction with analysis--but there's no shortage of skeptics in the field.

"Unfortunately, the science is not there yet," UC San Diego's Dr. Gregory Light tells the Austin American-Statesman. "Blood-based tests, at the moment, are far away from being useful for an individual patient. Most patients and families would prefer such a test that would yield easy, objective answers. Unfortunately, we do not have this yet."

CEO Craig Benson counters: "Diagnosing this illness is currently a subjective matter, and we think that providing an objective tool to assist the clinician will help bring about an earlier and more accurate diagnosis."

- here's the article from the Austin American-Statesman

Suggested Articles

The immunoassay will measure neurofilament light chain protein levels, found in the blood and cerebrospinal fluid, and linked to nerve damage.

Emmecell aims to make corneal transplant surgery, which can take up to a year to heal from and fails up to 20% of the time, a relic of the past.

Seven developers will provide digital health solutions aimed at the COVID-19 pandemic, including smartphone apps, wearables and big data programs.